Organ | 1 h | 4 h | 12 h | 24 h |
Blood | 3.5 ± 0.6 | 2.6 ± 0.8 | 2.3 ± 0.4 | 2.1 ± 0.5 |
Tumor | 4.1 ± 0.3 | 4.1 ± 0.6 | 4.2 ± 0.8 | 4.0 ± 0.9 |
Heart | 1.1 ± 0.2 | 0.9 ± 0.3 | 0.9 ± 0.1 | 0.8 ± 0.2 |
Lung | 1.6 ± 0.5 | 1.6 ± 0.4 | 1.1 ± 0.4 | 1.0 ± 0.3 |
Liver | 2.2 ± 0.3 | 1.3 ± 0.3 | 0.9 ± 0.2 | 1.1 ± 0.2 |
Spleen | 0.6 ± 0.1 | 0.5 ± 0.2 | 0.6 ± 0.3 | 0.4 ± 0.1 |
Stomach | 0.5 ± 0.1 | 0.3 ± 0.1 | 0.5 ± 0.6 | 0.2 ± 0.0 |
Large intestine | 0.5 ± 0.0 | 3.1 ± 1.1 | 2.3 ± 1.0 | 1.1 ± 0.4 |
Feces | 11.9 ± 4.4 | 8.8 ± 3.4 | 2.5 ± 0.1 | 1.4 ± 0.5 |
Small intestine | 0.0 ± 0.0 | 0.4 ± 0.1 | 0.8 ± 0.5 | 0.3 ± 0.0 |
Kidney | 1.3 ± 0.1 | 0.9 ± 0.3 | 0.9 ± 0.3 | 0.7 ± 0.2 |
Muscle | 0.2 ± 0.0 | 0.1 ± 0.0 | 0.2 ± 0.0 | 0.1 ± 0.0 |
Bone | 0.3 ± 0.2 | 0.3 ± 0.2 | 0.4 ± 0.1 | 0.3 ± 0.1 |
Skin | 0.3 ± 0.1 | 0.3 ± 0.1 | 0.4 ± 0.1 | 0.5 ± 0.2 |
Values are %ID/g ± SD. Mice (n = 4) bearing subcutaneous SW1222 xenografts were administered A33-TCO (100 μg) via tail vein injection. After 24 h, the same mice were administered 64Cu-Tz-Bn-NOTA (0.55–0.75 MBq [15–20 μCi]) via tail vein injection (t = 0).